Semaglutide

Applications:Semaglutide (English: Semaglutide), sold under the brand names Ozempic, Wegovy, and Rybelsus, is an antidiabetic drug for type 2 diabetes and a weight loss drug for long-term weight management developed by Novo Nordisk in 2012. It is a peptide similar to glucagon-like peptide-1 with a modified side chain. It can be injected subcutaneously or orally. Ozempic is used to treat type 2 diabetes, and Wegovy is used for weight loss.